Cycloserine Dosage

Medically reviewed by Drugs.com. Last updated on Jan 23, 2023.

Usual Adult Dose for Tuberculosis - Extrapulmonary

Initial dose: 250 mg orally every 12 hours for the first 2 weeks
Maintenance dose: 500 to 1000 mg orally per day, given in divided doses
Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be determined by blood levels.
• Treatment of urinary tract infections should be considered in patients for whom conventional therapy has failed, and when the organism has demonstrated susceptibility to this drug.
• This drug should be given concomitantly with other effective anti-tuberculous options; use of treatment as the only therapeutic agent should be avoided.

Uses:

• Treatment of active pulmonary and extrapulmonary tuberculosis (e.g., renal disease) with susceptible causative organisms AND when the response to primary treatment options (e.g., ethambutol, isoniazid, rifampin/rifamycin, streptomycin) are inadequate
• Treatment of acute urinary tract infections caused by susceptible gram-positive and negative bacteria

American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
10 to 15 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be titrated and determines by serum levels.
• This drug is usually given as 250 to 500 mg orally once to 2 times a day.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US Department of Health and Human Services (US HHS), and IDSA Recommendations:
10 to 15 mg/kg orally once to 2 times a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comments:

• This drug may be started with 250 mg orally once a day, and doses may be titrated based on serum levels.
• Some experts state that usual doses are 500 to 750 mg/day in 2 divided doses.

Uses:

• Second-line treatment of drug-resistant tuberculosis caused by Mycobacterium tuberculosis with known/presumed susceptibility
• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Temporary treatment of acute hepatitis in combination with other non-hepatotoxic drugs

US HHS, National Institutes of Health (NIH), Health Resources and Services Administration (HRSA), and US CDC Recommendations:
Initial dose: 250 mg orally once a day
Maintenance dose: 250 to 1000 mg orally per day, given once a day or in divided doses
Maximum dose: 1000 mg/day

Comments:

• This drug should be given via directly observed therapy (DOT).
• Initial doses may be increased based on tolerability.
• The recommended maintenance dose range is 10 to 15 mg/kg/day, given in 2 divided doses.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Adult Dose for Tuberculosis - HIV Positive

Initial dose: 250 mg orally every 12 hours for the first 2 weeks
Maintenance dose: 500 to 1000 mg orally per day, given in divided doses
Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be determined by blood levels.
• Treatment of urinary tract infections should be considered in patients for whom conventional therapy has failed, and when the organism has demonstrated susceptibility to this drug.
• This drug should be given concomitantly with other effective anti-tuberculous options; use of treatment as the only therapeutic agent should be avoided.

Uses:

• Treatment of active pulmonary and extrapulmonary tuberculosis (e.g., renal disease) with susceptible causative organisms AND when the response to primary treatment options (e.g., ethambutol, isoniazid, rifampin/rifamycin, streptomycin) are inadequate
• Treatment of acute urinary tract infections caused by susceptible gram-positive and negative bacteria

American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
10 to 15 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be titrated and determines by serum levels.
• This drug is usually given as 250 to 500 mg orally once to 2 times a day.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US Department of Health and Human Services (US HHS), and IDSA Recommendations:
10 to 15 mg/kg orally once to 2 times a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comments:

• This drug may be started with 250 mg orally once a day, and doses may be titrated based on serum levels.
• Some experts state that usual doses are 500 to 750 mg/day in 2 divided doses.

Uses:

• Second-line treatment of drug-resistant tuberculosis caused by Mycobacterium tuberculosis with known/presumed susceptibility
• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Temporary treatment of acute hepatitis in combination with other non-hepatotoxic drugs

US HHS, National Institutes of Health (NIH), Health Resources and Services Administration (HRSA), and US CDC Recommendations:
Initial dose: 250 mg orally once a day
Maintenance dose: 250 to 1000 mg orally per day, given once a day or in divided doses
Maximum dose: 1000 mg/day

Comments:

• This drug should be given via directly observed therapy (DOT).
• Initial doses may be increased based on tolerability.
• The recommended maintenance dose range is 10 to 15 mg/kg/day, given in 2 divided doses.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Adult Dose for Tuberculosis - Resistant

Initial dose: 250 mg orally every 12 hours for the first 2 weeks
Maintenance dose: 500 to 1000 mg orally per day, given in divided doses
Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be determined by blood levels.
• Treatment of urinary tract infections should be considered in patients for whom conventional therapy has failed, and when the organism has demonstrated susceptibility to this drug.
• This drug should be given concomitantly with other effective anti-tuberculous options; use of treatment as the only therapeutic agent should be avoided.

Uses:

• Treatment of active pulmonary and extrapulmonary tuberculosis (e.g., renal disease) with susceptible causative organisms AND when the response to primary treatment options (e.g., ethambutol, isoniazid, rifampin/rifamycin, streptomycin) are inadequate
• Treatment of acute urinary tract infections caused by susceptible gram-positive and negative bacteria

American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
10 to 15 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be titrated and determines by serum levels.
• This drug is usually given as 250 to 500 mg orally once to 2 times a day.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US Department of Health and Human Services (US HHS), and IDSA Recommendations:
10 to 15 mg/kg orally once to 2 times a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comments:

• This drug may be started with 250 mg orally once a day, and doses may be titrated based on serum levels.
• Some experts state that usual doses are 500 to 750 mg/day in 2 divided doses.

Uses:

• Second-line treatment of drug-resistant tuberculosis caused by Mycobacterium tuberculosis with known/presumed susceptibility
• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Temporary treatment of acute hepatitis in combination with other non-hepatotoxic drugs

US HHS, National Institutes of Health (NIH), Health Resources and Services Administration (HRSA), and US CDC Recommendations:
Initial dose: 250 mg orally once a day
Maintenance dose: 250 to 1000 mg orally per day, given once a day or in divided doses
Maximum dose: 1000 mg/day

Comments:

• This drug should be given via directly observed therapy (DOT).
• Initial doses may be increased based on tolerability.
• The recommended maintenance dose range is 10 to 15 mg/kg/day, given in 2 divided doses.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Adult Dose for Tuberculosis - Active

Initial dose: 250 mg orally every 12 hours for the first 2 weeks
Maintenance dose: 500 to 1000 mg orally per day, given in divided doses
Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be determined by blood levels.
• Treatment of urinary tract infections should be considered in patients for whom conventional therapy has failed, and when the organism has demonstrated susceptibility to this drug.
• This drug should be given concomitantly with other effective anti-tuberculous options; use of treatment as the only therapeutic agent should be avoided.

Uses:

• Treatment of active pulmonary and extrapulmonary tuberculosis (e.g., renal disease) with susceptible causative organisms AND when the response to primary treatment options (e.g., ethambutol, isoniazid, rifampin/rifamycin, streptomycin) are inadequate
• Treatment of acute urinary tract infections caused by susceptible gram-positive and negative bacteria

American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
10 to 15 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be titrated and determines by serum levels.
• This drug is usually given as 250 to 500 mg orally once to 2 times a day.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US Department of Health and Human Services (US HHS), and IDSA Recommendations:
10 to 15 mg/kg orally once to 2 times a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comments:

• This drug may be started with 250 mg orally once a day, and doses may be titrated based on serum levels.
• Some experts state that usual doses are 500 to 750 mg/day in 2 divided doses.

Uses:

• Second-line treatment of drug-resistant tuberculosis caused by Mycobacterium tuberculosis with known/presumed susceptibility
• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Temporary treatment of acute hepatitis in combination with other non-hepatotoxic drugs

US HHS, National Institutes of Health (NIH), Health Resources and Services Administration (HRSA), and US CDC Recommendations:
Initial dose: 250 mg orally once a day
Maintenance dose: 250 to 1000 mg orally per day, given once a day or in divided doses
Maximum dose: 1000 mg/day

Comments:

• This drug should be given via directly observed therapy (DOT).
• Initial doses may be increased based on tolerability.
• The recommended maintenance dose range is 10 to 15 mg/kg/day, given in 2 divided doses.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Adult Dose for Urinary Tract Infection

Initial dose: 250 mg orally every 12 hours for the first 2 weeks
Maintenance dose: 500 to 1000 mg orally per day, given in divided doses
Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be determined by blood levels.
• Treatment of urinary tract infections should be considered in patients for whom conventional therapy has failed, and when the organism has demonstrated susceptibility to this drug.
• This drug should be given concomitantly with other effective anti-tuberculous options; use of treatment as the only therapeutic agent should be avoided.

Uses:

• Treatment of active pulmonary and extrapulmonary tuberculosis (e.g., renal disease) with susceptible causative organisms AND when the response to primary treatment options (e.g., ethambutol, isoniazid, rifampin/rifamycin, streptomycin) are inadequate
• Treatment of acute urinary tract infections caused by susceptible gram-positive and negative bacteria

American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
10 to 15 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comments:

• Maintenance doses should be titrated and determines by serum levels.
• This drug is usually given as 250 to 500 mg orally once to 2 times a day.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US Department of Health and Human Services (US HHS), and IDSA Recommendations:
10 to 15 mg/kg orally once to 2 times a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comments:

• This drug may be started with 250 mg orally once a day, and doses may be titrated based on serum levels.
• Some experts state that usual doses are 500 to 750 mg/day in 2 divided doses.

Uses:

• Second-line treatment of drug-resistant tuberculosis caused by Mycobacterium tuberculosis with known/presumed susceptibility
• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Temporary treatment of acute hepatitis in combination with other non-hepatotoxic drugs

US HHS, National Institutes of Health (NIH), Health Resources and Services Administration (HRSA), and US CDC Recommendations:
Initial dose: 250 mg orally once a day
Maintenance dose: 250 to 1000 mg orally per day, given once a day or in divided doses
Maximum dose: 1000 mg/day

Comments:

• This drug should be given via directly observed therapy (DOT).
• Initial doses may be increased based on tolerability.
• The recommended maintenance dose range is 10 to 15 mg/kg/day, given in 2 divided doses.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Adult Dose for Mycobacterium avium-intracellulare - Treatment

US HHS, NIH, HRSA, and US CDC Recommendations:
5 mg/kg orally 2 times per day

• Maximum dose: 1000 mg/day

Comments:

• Use is supported by anecdotal evidence.
• Antiretroviral therapy (ART) should be optimized in patients with unsuccessful initial treatment OR with resistance to antimycobacterial agents.

Use: Second-line adjunct therapy (with azithromycin/clarithromycin and other drugs as salvage therapy) in the treatment of Mycobacterium avium intracellulare complex (MAC) in patients with HIV

Usual Pediatric Dose for Tuberculosis - Extrapulmonary

American Academy of Pediatrics (AAP) Recommendations:
Infants, children, and adolescents: 10 to 20 mg/kg orally per day, given in 2 divided doses

• Maximum dose: 1 gram/day

Use: Adjunctive treatment of drug-resistant tuberculosis

ATS, US CDC, and IDSA Recommendations:
Children: 15 to 20 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comment: Maintenance doses should be titrated and based on serum levels.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US HHS, and IDSA Recommendations:
Children: 10 to 15 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comment: Maintenance doses should be titrated and based on serum levels.

Uses:

• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Second-line treatment of drug-resistant tuberculosis caused by organisms with known/presumed susceptibility to the agent
• Temporary treatment of acute hepatitis in combination with other nonhepatotoxic drugs

US HHS, NIH, HRSA, and US CDC Recommendations:
Children: 10 to 20 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: At least 12 months (minimal disease); 18 to 24 months (after non-bacteriological diagnosis OR after culture conversion)

Comments:

• This drug should be given via DOT.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Pediatric Dose for Tuberculosis - HIV Positive

American Academy of Pediatrics (AAP) Recommendations:
Infants, children, and adolescents: 10 to 20 mg/kg orally per day, given in 2 divided doses

• Maximum dose: 1 gram/day

Use: Adjunctive treatment of drug-resistant tuberculosis

ATS, US CDC, and IDSA Recommendations:
Children: 15 to 20 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comment: Maintenance doses should be titrated and based on serum levels.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US HHS, and IDSA Recommendations:
Children: 10 to 15 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comment: Maintenance doses should be titrated and based on serum levels.

Uses:

• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Second-line treatment of drug-resistant tuberculosis caused by organisms with known/presumed susceptibility to the agent
• Temporary treatment of acute hepatitis in combination with other nonhepatotoxic drugs

US HHS, NIH, HRSA, and US CDC Recommendations:
Children: 10 to 20 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: At least 12 months (minimal disease); 18 to 24 months (after non-bacteriological diagnosis OR after culture conversion)

Comments:

• This drug should be given via DOT.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Pediatric Dose for Tuberculosis - Resistant

American Academy of Pediatrics (AAP) Recommendations:
Infants, children, and adolescents: 10 to 20 mg/kg orally per day, given in 2 divided doses

• Maximum dose: 1 gram/day

Use: Adjunctive treatment of drug-resistant tuberculosis

ATS, US CDC, and IDSA Recommendations:
Children: 15 to 20 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comment: Maintenance doses should be titrated and based on serum levels.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US HHS, and IDSA Recommendations:
Children: 10 to 15 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comment: Maintenance doses should be titrated and based on serum levels.

Uses:

• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Second-line treatment of drug-resistant tuberculosis caused by organisms with known/presumed susceptibility to the agent
• Temporary treatment of acute hepatitis in combination with other nonhepatotoxic drugs

US HHS, NIH, HRSA, and US CDC Recommendations:
Children: 10 to 20 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: At least 12 months (minimal disease); 18 to 24 months (after non-bacteriological diagnosis OR after culture conversion)

Comments:

• This drug should be given via DOT.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Usual Pediatric Dose for Tuberculosis - Active

American Academy of Pediatrics (AAP) Recommendations:
Infants, children, and adolescents: 10 to 20 mg/kg orally per day, given in 2 divided doses

• Maximum dose: 1 gram/day

Use: Adjunctive treatment of drug-resistant tuberculosis

ATS, US CDC, and IDSA Recommendations:
Children: 15 to 20 mg/kg orally, given in divided doses 1 to 2 times a day

• Maximum dose: 1000 mg/day

Comment: Maintenance doses should be titrated and based on serum levels.

Use: Second-line treatment of tuberculosis caused by known/suspected drug-susceptible organisms

ATS, US CDC, US HHS, and IDSA Recommendations:
Children: 10 to 15 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: Up to 18 to 24 months

Comment: Maintenance doses should be titrated and based on serum levels.

Uses:

• Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
• Second-line treatment of drug-resistant tuberculosis caused by organisms with known/presumed susceptibility to the agent
• Temporary treatment of acute hepatitis in combination with other nonhepatotoxic drugs

US HHS, NIH, HRSA, and US CDC Recommendations:
Children: 10 to 20 mg/kg orally once a day

• Maximum dose: 1000 mg/day
• Duration of therapy: At least 12 months (minimal disease); 18 to 24 months (after non-bacteriological diagnosis OR after culture conversion)

Comments:

• This drug should be given via DOT.
• Toxicities and drug-drug interactions should be reviewed at each visit.

Use: Second-line adjunctive treatment of drug-resistant tuberculosis in patients with HIV

Renal Dose Adjustments

Children and adults:

• Mild to moderate renal dysfunction: Frequent drug level monitoring (e.g., at least once a week) recommended.
• Severe renal dysfunction: Contraindicated

Older patients:

• Mild to moderate renal dysfunction: Doses should be adjusted to maintain blood concentrations below 30 mcg/mL.
• Severe renal dysfunction: Contraindicated

ATS, US CDC, US HHS, and IDSA Recommendations:
Adults:

• CrCl less than 50 mL/min, but not receiving hemodialysis: Not recommended.

Comment: Serum levels and monitoring for neurotoxicity should be performed.

Uses:

• Second-line treatment of drug-resistant tuberculosis caused by organisms with known/presumed susceptibility to the agent
• Temporary treatment of acute hepatitis in combination with other nonhepatotoxic drugs

Some experts recommend:
Adults:

• CrCl less than 30 mL/min: 250 mg orally once a day OR 500 mg orally 3 times a week

US HHS, NIH, HRSA, and US CDC Recommendations:
Adults:

• CrCl 50 to 80 mL/min: Frequent monitoring should be considered.
• CrCl less than 50 mL/min, but not receiving hemodialysis: Not recommended.

Liver Dose Adjustments

Frequent liver function monitoring recommended.

ATS, US CDC, and IDSA Recommendations:
Adults:
Severe, unstable liver disease: 250 mg orally once a day OR 500 mg orally 3 times a week and rifabutin, PLUS a fluoroquinolone and/or second-line injectable agent

• Duration of therapy: Approximately 12 to 18 months (disease and response-dependent)

Comments:

• Serum levels and monitoring for neurotoxicity should be performed.
• When used in combination with ethambutol, a fluoroquinolone, and second line-injectable agent, this regimen has little to no potential hepatic toxicity.

Use: Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms in patients with advanced liver dysfunction

Dose Adjustments

Allergic dermatitis or signs/symptoms of central nervous system (CNS) toxicity: Administration should be discontinued OR the dosage should be reduced

Anemia, folic acid deficiency, and/or vitamin B12: Further investigation and appropriate treatment should be started.

Hematological studies should be regularly assessed.

Therapeutic drug monitoring/range: Blood concentrations should be below 30 mcg/mL

• Blood levels over 30 mcg/mL: Doses should be decreased to maintain blood levels below 30 mcg/mL.

Monitoring should be conducted at least once a week in:

• Patients receiving doses over 500 mg/day
• Patients with signs/symptoms suggesting toxicity
• Renal dysfunction

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or to any of the ingredients
• Patients with depression, psychosis, or severe anxiety
• Patients with epilepsy
• Patients with excessive concurrent use of alcohol
• Severe renal dysfunction

Safety and efficacy have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

ATS, US CDC, and IDSA Recommendations:
Adults:
Hemodialysis: 250 mg orally once a day OR 500 mg orally 3 times a week

Comments:

• Serum levels should be measured and monitoring for neurotoxicity should be performed.
• Treatment should be given after hemodialysis on the day of hemodialysis.

Use: Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms

Other Comments

Storage requirements:

• Protect from moisture.

Monitoring:

• GENERAL: Drug levels routinely, especially in those with renal dysfunction, receiving higher daily doses, and/or with signs/symptoms of toxicity
• HEMATOLOGIC: Hematological function studies
• HEPATIC: Liver function studies
• IMMUNOLOGIC: Susceptibility tests to confirm susceptibility to this drug prior to initiation, and repeated throughout treatment; repeat tests for persistent positive cultures
• RENAL: Renal function studies

Patient advice:

• Inform patients that this drug may cause dizziness, and they should avoid driving or operating machinery if these side effects occur.
• Patients should be instructed to avoid alcohol during treatment.
• Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer